Dr. Rita Nanda
Hematology & Oncology (Hematology & Oncology Physician)
5841 S Maryland Ave
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 94
Licensed in Illinois since 2000, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036103784 (first issued 2000; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
Medical groups
- University of Chicago (1,712 clinicians)
- The University of Chicago Medical Center (915 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 94
- Services billed
- 234
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 73 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 62 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 33 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ibrance (palbociclib) | 28 |
| Exemestane | 26 |
| Kisqali (ribociclib succinate) | 25 |
| Anastrozole Other prescribers in Chicago, IL | 23 |
| Letrozole Other prescribers in Chicago, IL | 15 |
| Gabapentin Other prescribers in Chicago, IL | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 41 payments worth $38,168 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $14,952 |
|---|---|
| Gilead Sciences, Inc. | $8,699 |
| Pfizer Inc. | $6,234 |
| Corcept Therapeutics | $4,655 |
| Daiichi Sankyo Inc. | $3,312 |
| Stemline Therapeutics Inc. | $181 |
| AstraZeneca UK Limited | $135 |
| Consulting Fee | $31,604 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $4,606 |
| Food and Beverage | $1,009 |
| Speaking at a medical education program | $843 |
| Travel and Lodging | $107 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Nov 26, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4253412;VEM US;10620187 | $6,060 |
| Corcept Therapeutics Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,606 |
| AstraZeneca Pharmaceuticals LP Sep 11, 2025 | Consulting Fee | $4,100 |
| Pfizer Inc. Apr 14, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $3,200 |
| AstraZeneca Pharmaceuticals LP Feb 11, 2025 | Consulting Fee | $2,460 |
| Gilead Sciences, Inc. Jul 16, 2025 | Consulting FeeCompany’s description;4280037;GTF;10620187 | $2,180 |
| AstraZeneca Pharmaceuticals LP Feb 21, 2025 | Consulting Fee | $2,055 |
| AstraZeneca Pharmaceuticals LP Feb 10, 2025 | Consulting Fee | $2,055 |
| Pfizer Inc. Jan 7, 2025 | Consulting Fee | $1,800 |
| AstraZeneca Pharmaceuticals LP Feb 10, 2025 | Consulting Fee | $1,640 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Dec 23, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $343 |
| Corcept Therapeutics Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,606 |
| Pfizer Inc. Dec 10, 2025 | Consulting Fee | $360 |
| Gilead Sciences, Inc. Nov 26, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4253412;VEM US;10620187 | $6,060 |
| Gilead Sciences, Inc. Nov 14, 2025 | Travel and Lodging Trodelvy · ONC · travel to Chicago, IL Company’s description;4253575;VEM US;10620187 | $36.00 |
| Gilead Sciences, Inc. Nov 14, 2025 | Travel and Lodging Trodelvy · ONC · travel to Chicago, IL Company’s description;4253463;VEM US;10620187 | $23.80 |
| AstraZeneca Pharmaceuticals LP Sep 11, 2025 | Consulting Fee | $4,100 |
| Daiichi Sankyo Inc. Aug 13, 2025 | Consulting Fee Enhertu · ONCOLOGY | $685 |
| AstraZeneca Pharmaceuticals LP Aug 11, 2025 | Consulting Fee | $410 |
| Pfizer Inc. Aug 6, 2025 | Consulting Fee | $800 |
| AstraZeneca Pharmaceuticals LP Aug 6, 2025 | Consulting Fee | $410 |
| Gilead Sciences, Inc. Jul 16, 2025 | Consulting FeeCompany’s description;4280037;GTF;10620187 | $2,180 |
| Gilead Sciences, Inc. May 29, 2025 | Travel and Lodging travel to Chicago, IL Company’s description;4280031;GTF;10620187 | $32.00 |
| Daiichi Sankyo Inc. May 7, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $1,028 |
| AstraZeneca Pharmaceuticals LP Apr 21, 2025 | Consulting Fee | $820 |
| Pfizer Inc. Apr 14, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $3,200 |
| Daiichi Sankyo Inc. Apr 9, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $1,199 |
| AstraZeneca Pharmaceuticals LP Mar 31, 2025 | Speaking at a medical education program | $843 |
| AstraZeneca Pharmaceuticals LP Mar 31, 2025 | Travel and Lodging travel to Chicago, IL | $15.15 |
| AstraZeneca Pharmaceuticals LP Feb 21, 2025 | Consulting Fee | $2,055 |
| AstraZeneca Pharmaceuticals LP Feb 11, 2025 | Consulting Fee | $2,460 |
| AstraZeneca Pharmaceuticals LP Feb 10, 2025 | Consulting Fee | $2,055 |
| AstraZeneca Pharmaceuticals LP Feb 10, 2025 | Consulting Fee | $1,640 |
| Pfizer Inc. Jan 7, 2025 | Consulting Fee | $1,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $197,351 in research payments for these studies, mostly to the institutions running them.
- Phase II Study of Pembrolizumab and Mifepristone in Patients with Advanced HER2-negative Breast Cancer
Merck Sharp & Dohme LLC - A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast C…
Merck Sharp & Dohme LLC - PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial
Jazz Pharmaceuticals Inc. - I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Jazz Pharmaceuticals Inc. - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT01042379 - A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - K…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.